Virtual memory CD8+ T cells restrain the viral reservoir in HIV-1-infected patients with antiretroviral therapy through derepressing KIR-mediated inhibition
- PMID: 32210395
- PMCID: PMC7784989
- DOI: 10.1038/s41423-020-0408-9
Virtual memory CD8+ T cells restrain the viral reservoir in HIV-1-infected patients with antiretroviral therapy through derepressing KIR-mediated inhibition
Abstract
The viral reservoir is the major hurdle in developing and establishing an HIV cure. Understanding factors affecting the size and decay of this reservoir is crucial for the development of therapeutic strategies. Recent work highlighted that CD8+ T cells are involved in the control of viral replication in ART-treated HIV-1-infected individuals, but how CD8+ T cells sense and restrict the HIV reservoir are not fully understood. Here, we demonstrate that a population of unconventional CD45RA+, PanKIR+, and/or NKG2A+ virtual memory CD8+ T cells (TVM cells), which confer rapid and robust protective immunity against pathogens, plays an important role in restraining the HIV DNA reservoir in HIV-1-infected patients with effective ART. In patients undergoing ART, TVM cells negatively correlate with HIV DNA and positively correlate with circulating IFN-α2 and IL-15. Moreover, TVM cells constitutively express high levels of cytotoxic granule components, including granzyme B, perforin and granulysin, and demonstrate the capability to control HIV replication through both cytolytic and noncytolytic mechanisms. Furthermore, by using an ex vivo system, we showed that HIV reactivation is effectively suppressed by TVM cells through KIR-mediated recognition. This study suggests that TVM cells are a promising target to predict posttreatment virological control and to design immune-based interventions to reduce the reservoir size in ART-treated HIV-1-infected individuals.
Keywords: HIV reservoir; KIR; virtual memory CD8+ T cells.
Conflict of interest statement
The authors declare no competing interests.
Figures
Comment in
-
Bystanders or real players: virtual memory T cells keep chronic infections in check.Cell Mol Immunol. 2020 Aug;17(8):797-798. doi: 10.1038/s41423-020-0469-9. Epub 2020 May 25. Cell Mol Immunol. 2020. PMID: 32451451 Free PMC article. No abstract available.
-
Unconventional CD45RA+ memory CD8 T cells to control HIV infection during antiretroviral therapy.Cell Mol Immunol. 2020 Sep;17(9):897-898. doi: 10.1038/s41423-020-0478-8. Epub 2020 Jun 5. Cell Mol Immunol. 2020. PMID: 32503999 Free PMC article. No abstract available.
Similar articles
-
CCL5-Secreting Virtual Memory CD8+ T Cells Inversely Associate With Viral Reservoir Size in HIV-1-Infected Individuals on Antiretroviral Therapy.Front Immunol. 2022 May 26;13:897569. doi: 10.3389/fimmu.2022.897569. eCollection 2022. Front Immunol. 2022. PMID: 35720272 Free PMC article.
-
HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection.J Virol. 2017 Mar 29;91(8):e02233-16. doi: 10.1128/JVI.02233-16. Print 2017 Apr 15. J Virol. 2017. PMID: 28179527 Free PMC article.
-
CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.J Virol. 2016 Jul 11;90(15):6818-6831. doi: 10.1128/JVI.00276-16. Print 2016 Aug 1. J Virol. 2016. PMID: 27194762 Free PMC article.
-
The role of CD8 T cells in controlling HIV beyond the antigen-specific face.HIV Med. 2020 Dec;21(11):692-700. doi: 10.1111/hiv.13021. HIV Med. 2020. PMID: 33369032 Review.
-
Blocking Formation of the Stable HIV Reservoir: A New Perspective for HIV-1 Cure.Front Immunol. 2019 Aug 22;10:1966. doi: 10.3389/fimmu.2019.01966. eCollection 2019. Front Immunol. 2019. PMID: 31507594 Free PMC article. Review.
Cited by
-
Elevated glutamate impedes anti-HIV-1 CD8 + T cell responses in HIV-1-infected individuals on antiretroviral therapy.Commun Biol. 2023 Jul 7;6(1):696. doi: 10.1038/s42003-023-04975-z. Commun Biol. 2023. PMID: 37419968 Free PMC article.
-
Characteristics of refined lymphocyte subsets changes in people living with HIV/AIDS during antiretroviral therapy period: An observation from Wuhan, China.Front Immunol. 2023 Feb 9;14:1089379. doi: 10.3389/fimmu.2023.1089379. eCollection 2023. Front Immunol. 2023. PMID: 36845097 Free PMC article.
-
Expansion of an Unusual Virtual Memory CD8+ Subpopulation Bearing Vα3.2 TCR in Themis-Deficient Mice.Front Immunol. 2021 Apr 7;12:644483. doi: 10.3389/fimmu.2021.644483. eCollection 2021. Front Immunol. 2021. PMID: 33897691 Free PMC article.
-
New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection.Front Immunol. 2022 Jan 4;12:719664. doi: 10.3389/fimmu.2021.719664. eCollection 2021. Front Immunol. 2022. PMID: 35058917 Free PMC article. Review.
-
Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV.EBioMedicine. 2022 Jul;81:104090. doi: 10.1016/j.ebiom.2022.104090. Epub 2022 Jun 2. EBioMedicine. 2022. PMID: 35665682 Free PMC article.
References
-
- Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49–62. - PubMed
-
- Furtado MR, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 1999;340:1614–1622. - PubMed
-
- Hocqueloux L, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. Aids. 2010;24:1598–1601. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials